Brandon Kovarovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brandon Kovarovic has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Danny Bluestein
Department of Biomedical Engineering, Stony Brook University, Stony Brook, USA
11 shared publications Oren M. Rotman
Biofluids Research Group Department of Biomedical Engineering Stony Brook University Stony Brook NY USA
5 shared publications- Marvin J. Slepian
Department of Computer Sciences, University of Arizona, Tucson, USA
4 shared publications Matteo Bianchi
Department of Biomedical Engineering Stony Brook University Stony Brook New York USA
4 shared publicationsSalwa Anam
Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794, USA
3 shared publications- Symon Reza
Department of Biomedical Engineering, Stony Brook University
3 shared publications
Latest Publications
- Open Access
Impact of Aortic Valve Leaflets Calcium Volume and Distribution on Post-TAVR Conduction Abnormalities
Introduction Transcatheter aortic valve replacement (TAVR) is increasingly used to treat aortic stenosis, including in low-risk patients. However, post-procedural cardiac conduction abnormalities (CCA), often requiring permanent pacemaker implantation (PPI), remain a concern. This study investigates how the volume and distribution of aortic leaflet calcium deposits influence the risk of post-TAVR CCA. Methods An electromechanically coupled four-chamber beating heart model was used to simulate TAVR with a self-expandable Evolut® 26 mm device. Five virtual patient scenarios were modeled with varying calcium volumes and distributions: no calcium, uniform distribution (3 Calc), and isolated calcification on the left coronary leaflet (LCL), right coronary leaflet (RCL), or non-coronary leaflet (NCL). Electrical conduction was simulated using a monodomain model and coupled with structural mechanics to evaluate tissue-device interactions. Metrics included principal stress, contact pressure, and contact pressure index (CPI) over three cardiac cycles. Results Larger calcium volumes and specific leaflet distributions increased stress and contact pressure near the atrioventricular node. The LCL model exhibited the highest mechanical stress and peak contact pressure (13.1 kPa), while the NCL model showed the lowest (6.42 kPa). The RCL model had intermediate values. Elevated contact pressure and stress in the LCL case suggest an increased risk of conduction disruption and PPI. Conclusion Leaflet calcium deposit volume and distribution significantly influence mechanical stress and contact dynamics near the conduction system following TAVR. These insights support the integration of clinical data, such as leaflet calcium volume and distribution into pre-procedural planning to personalize risk assessment and improve patient outcomes. Highlights Beating heart model used to assess post-TAVR conduction abnormality risk. Higher calcium volume increases contact pressure near conduction pathways. Left coronary leaflet calcification linked to elevated post-TAVR CCA risk. Dynamic simulations show stress fluctuations during cardiac cycles. Findings support personalized TAVR planning to reduce PPI need.
Open AccessImpact of Aortic Valve Leaflets Calcium Volume and Distribution on Post-TAVR Conduction Abnormalities
Introduction Transcatheter aortic valve replacement (TAVR) is increasingly used to treat aortic stenosis, including in low-risk patients. However, post-procedural cardiac conduction abnormalities (CCA), often requiring permanent pacemaker implantation (PPI), remain a concern. This study investigates how the volume and distribution of aortic leaflet calcium deposits influence the risk of post-TAVR CCA. Methods An electromechanically coupled four-chamber beating heart model was used to simulate TAVR with a self-expandable Evolut® 26 mm device. Five virtual patient scenarios were modeled with varying calcium volumes and distributions: no calcium, uniform distribution (3 Calc), and isolated calcification on the left coronary leaflet (LCL), right coronary leaflet (RCL), or non-coronary leaflet (NCL). Electrical conduction was simulated using a monodomain model and coupled with structural mechanics to evaluate tissue-device interactions. Metrics included principal stress, contact pressure, and contact pressure index (CPI) over three cardiac cycles. Results Larger calcium volumes and specific leaflet distributions increased stress and contact pressure near the atrioventricular node. The LCL model exhibited the highest mechanical stress and peak contact pressure (13.1 kPa), while the NCL model showed the lowest (6.42 kPa). The RCL model had intermediate values. Elevated contact pressure and stress in the LCL case suggest an increased risk of conduction disruption and PPI. Conclusion Leaflet calcium deposit volume and distribution significantly influence mechanical stress and contact dynamics near the conduction system following TAVR. These insights support the integration of clinical data, such as leaflet calcium volume and distribution into pre-procedural planning to personalize risk assessment and improve patient outcomes. Highlights Beating heart model used to assess post-TAVR conduction abnormality risk. Higher calcium volume increases contact pressure near conduction pathways. Left coronary leaflet calcification linked to elevated post-TAVR CCA risk. Dynamic simulations show stress fluctuations during cardiac cycles. Findings support personalized TAVR planning to reduce PPI need.
- 29 October 2024
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 257, 108469
Thrombogenic Risk Assessment of Transcatheter Prosthetic Heart Valves Using a Fluid-Structure Interaction Approach
- 29 October 2024
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 257, 108469
Thrombogenic Risk Assessment of Transcatheter Prosthetic Heart Valves Using a Fluid-Structure Interaction Approach
- Open Access
Assessing Post-TAVR Cardiac Conduction Abnormalities Risk Using a Digital Twin of a Beating Heart
Transcatheter aortic valve replacement (TAVR) has rapidly displaced surgical aortic valve replacement (SAVR). However, certain post-TAVR complications persist, with cardiac conduction abnormalities (CCA) being one of the major ones. The elevated pressure exerted by the TAVR stent onto the conduction fibers situated between the aortic annulus and the His bundle, in proximity to the atrioventricular (AV) node, may disrupt the cardiac conduction leading to the emergence of CCA. In his study, an in-silico framework was developed to assess the CCA risk, incorporating the effect of a dynamic beating heart and pre-procedural parameters such as implantation depth and preexisting cardiac asynchrony in the new onset of post-TAVR CCA. A self-expandable TAVR device deployment was simulated inside an electro-mechanically coupled beating heart model in five patient scenarios, including three implantation depths, and two preexisting cardiac asynchronies: (i) a right bundle branch block (RBBB) and (ii) a left bundle branch block (LBBB). Subsequently, several biomechanical parameters were analyzed to assess the post-TAVR CCA risk. The results manifested a lower cumulative contact pressure on the conduction fibers following TAVR for aortic deployment (0.018 MPa) compared to baseline (0.29 MPa) and ventricular deployment (0.52 MPa). Notably, the preexisting RBBB demonstrated a higher cumulative contact pressure (0.34 MPa) compared to the baseline and preexisting LBBB (0.25 MPa). Deeper implantation and preexisting RBBB cause higher stresses and contact pressure on the conduction fibers leading to an increased risk of post-TAVR CCA. Conversely, implantation above the MS landmark and preexisting LBBB reduces the risk.
Open AccessAssessing Post-TAVR Cardiac Conduction Abnormalities Risk Using a Digital Twin of a Beating Heart
Transcatheter aortic valve replacement (TAVR) has rapidly displaced surgical aortic valve replacement (SAVR). However, certain post-TAVR complications persist, with cardiac conduction abnormalities (CCA) being one of the major ones. The elevated pressure exerted by the TAVR stent onto the conduction fibers situated between the aortic annulus and the His bundle, in proximity to the atrioventricular (AV) node, may disrupt the cardiac conduction leading to the emergence of CCA. In his study, an in-silico framework was developed to assess the CCA risk, incorporating the effect of a dynamic beating heart and pre-procedural parameters such as implantation depth and preexisting cardiac asynchrony in the new onset of post-TAVR CCA. A self-expandable TAVR device deployment was simulated inside an electro-mechanically coupled beating heart model in five patient scenarios, including three implantation depths, and two preexisting cardiac asynchronies: (i) a right bundle branch block (RBBB) and (ii) a left bundle branch block (LBBB). Subsequently, several biomechanical parameters were analyzed to assess the post-TAVR CCA risk. The results manifested a lower cumulative contact pressure on the conduction fibers following TAVR for aortic deployment (0.018 MPa) compared to baseline (0.29 MPa) and ventricular deployment (0.52 MPa). Notably, the preexisting RBBB demonstrated a higher cumulative contact pressure (0.34 MPa) compared to the baseline and preexisting LBBB (0.25 MPa). Deeper implantation and preexisting RBBB cause higher stresses and contact pressure on the conduction fibers leading to an increased risk of post-TAVR CCA. Conversely, implantation above the MS landmark and preexisting LBBB reduces the risk.
- 25 October 2023
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 243, 107886
In silico fatigue optimization of TAVR stent designs with physiological motion in a beating heart model
- 25 October 2023
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 243, 107886
In silico fatigue optimization of TAVR stent designs with physiological motion in a beating heart model
- Open Access
- 1 February 2023
- Published by MDPI AG in Bioengineering
- Vol. 10 (2) , 188
Mild Paravalvular Leak May Pose an Increased Thrombogenic Risk in Transcatheter Aortic Valve Replacement (TAVR) Patients-Insights from Patient Specific In Vitro and In Silico Studies
In recent years, the treatment of aortic stenosis with TAVR has rapidly expanded to younger and lower-risk patients. However, persistent thrombotic events such as stroke and valve thrombosis expose recipients to severe clinical complications that hamper TAVR’s rapid advance. We presented a novel methodology for establishing a link between commonly acceptable mild paravalvular leak (PVL) levels through the device and increased thrombogenic risk. It utilizes in vitro patient-specific TAVR 3D-printed replicas evaluated for hydrodynamic performance. High-resolution µCT scans are used to reconstruct in silico FSI models of these replicas, in which multiple platelet trajectories are studied through the PVL channels to quantify thrombogenicity, showing that those are highly dependent on patient-specific flow conditions within the PVL channels. It demonstrates that platelets have the potential to enter the PVL channels multiple times over successive cardiac cycles, increasing the thrombogenic risk. This cannot be reliably approximated by standard hemodynamic parameters. It highlights the shortcomings of subjectively ranked PVL commonly used in clinical practice by indicating an increased thrombogenic risk in patient cases otherwise classified as mild PVL. It reiterates the need for more rigorous clinical evaluation for properly diagnosing thrombogenic risk in TAVR patients.
- 1 February 2023
- Published by MDPI AG in Bioengineering
- Vol. 10 (2) , 188
Open AccessMild Paravalvular Leak May Pose an Increased Thrombogenic Risk in Transcatheter Aortic Valve Replacement (TAVR) Patients-Insights from Patient Specific In Vitro and In Silico Studies
In recent years, the treatment of aortic stenosis with TAVR has rapidly expanded to younger and lower-risk patients. However, persistent thrombotic events such as stroke and valve thrombosis expose recipients to severe clinical complications that hamper TAVR’s rapid advance. We presented a novel methodology for establishing a link between commonly acceptable mild paravalvular leak (PVL) levels through the device and increased thrombogenic risk. It utilizes in vitro patient-specific TAVR 3D-printed replicas evaluated for hydrodynamic performance. High-resolution µCT scans are used to reconstruct in silico FSI models of these replicas, in which multiple platelet trajectories are studied through the PVL channels to quantify thrombogenicity, showing that those are highly dependent on patient-specific flow conditions within the PVL channels. It demonstrates that platelets have the potential to enter the PVL channels multiple times over successive cardiac cycles, increasing the thrombogenic risk. This cannot be reliably approximated by standard hemodynamic parameters. It highlights the shortcomings of subjectively ranked PVL commonly used in clinical practice by indicating an increased thrombogenic risk in patient cases otherwise classified as mild PVL. It reiterates the need for more rigorous clinical evaluation for properly diagnosing thrombogenic risk in TAVR patients.
- 6 April 2022
- Published by ASME International in Journal of Biomechanical Engineering
- Vol. 144 (6)
Visions of TAVR Future: Development and Optimization of a Second Generation Novel Polymeric TAVR
Tissue-based transcatheter aortic valve (AV) replacement (TAVR) devices have been a breakthrough approach for treating aortic valve stenosis. However, with the expansion of TAVR to younger and lower risk patients, issues of long-term durability and thrombosis persist. Recent advances in polymeric valve technology facilitate designing more durable valves with minimal in vivo adverse reactions. We introduce our second-generation polymeric transcatheter aortic valve (TAV) device, designed and optimized to address these issues. We present the optimization process of the device, wherein each aspect of device deployment and functionality was optimized for performance, including unique considerations of polymeric technologies for reducing the volume of the polymer material for lower crimped delivery profiles. The stent frame was optimized to generate larger radial forces with lower material volumes, securing robust deployment and anchoring. The leaflet shape, combined with varying leaflets thickness, was optimized for reducing the flexural cyclic stresses and the valve's hydrodynamics. Our first-generation polymeric device already demonstrated that its hydrodynamic performance meets and exceeds tissue devices for both ISO standard and patient-specific in vitro scenarios. The valve already reached 900 × 106 cycles of accelerated durability testing, equivalent to over 20 years in a patient. The optimization framework and technology led to the second generation of polymeric TAV design- currently undergoing in vitro hydrodynamic testing and following in vivo animal trials. As TAVR use is rapidly expanding, our rigorous bio-engineering optimization methodology and advanced polymer technology serve to establish polymeric TAV technology as a viable alternative to the challenges facing existing tissue-based TAV technology.
- 6 April 2022
- Published by ASME International in Journal of Biomechanical Engineering
- Vol. 144 (6)
Visions of TAVR Future: Development and Optimization of a Second Generation Novel Polymeric TAVR
Tissue-based transcatheter aortic valve (AV) replacement (TAVR) devices have been a breakthrough approach for treating aortic valve stenosis. However, with the expansion of TAVR to younger and lower risk patients, issues of long-term durability and thrombosis persist. Recent advances in polymeric valve technology facilitate designing more durable valves with minimal in vivo adverse reactions. We introduce our second-generation polymeric transcatheter aortic valve (TAV) device, designed and optimized to address these issues. We present the optimization process of the device, wherein each aspect of device deployment and functionality was optimized for performance, including unique considerations of polymeric technologies for reducing the volume of the polymer material for lower crimped delivery profiles. The stent frame was optimized to generate larger radial forces with lower material volumes, securing robust deployment and anchoring. The leaflet shape, combined with varying leaflets thickness, was optimized for reducing the flexural cyclic stresses and the valve's hydrodynamics. Our first-generation polymeric device already demonstrated that its hydrodynamic performance meets and exceeds tissue devices for both ISO standard and patient-specific in vitro scenarios. The valve already reached 900 × 106 cycles of accelerated durability testing, equivalent to over 20 years in a patient. The optimization framework and technology led to the second generation of polymeric TAV design- currently undergoing in vitro hydrodynamic testing and following in vivo animal trials. As TAVR use is rapidly expanding, our rigorous bio-engineering optimization methodology and advanced polymer technology serve to establish polymeric TAV technology as a viable alternative to the challenges facing existing tissue-based TAV technology.
- 7 February 2022
- Published by Wiley in Artificial Organs
- Vol. 46 (7) , 1305-1317
A computational framework for post‐TAVR cardiac conduction abnormality (CCA) risk assessment in patient‐specific anatomy
Background: Cardiac conduction abnormality (CCA)‐ one of the major persistent complications associated with transcatheter aortic valve replacement (TAVR) may lead to permanent pacemaker implantation. Localized stresses exerted by the device frame on the membranous septum (MS) which lies between the aortic annulus and the bundle of His, may disturb the cardiac conduction and cause the resultant CCA. We hypothesize that the area‐weighted average maximum principal logarithmic strain (AMPLS) in the MS region can predict the risk of CCA following TAVR.Methods: Rigorous finite element‐based analysis was conducted in two patients (Balloon expandable TAVR recipients) to assess post‐TAVR CCA risk. Following the procedure one of the patients required permanent pacemaker (PPM) implantation while the other did not (control case). Patient‐specific aortic root was modeled, MS was identified from the CT image, and the TAVR deployment was simulated. Mechanical factors in the MS region such as logarithmic strain, contact force, contact pressure, contact pressure index (CPI) and their time history during the TAVR deployment; and anatomical factors such as MS length, implantation depth, were analyzed.Results: Maximum AMPLS (0.47 and 0.37, respectively), contact force (0.92 N and 0.72 N, respectively), and CPI (3.99 and 2.86, respectively) in the MS region were significantly elevated in the PPM patient as compared to control patient.Conclusion: Elevated stresses generated by TAVR devices during deployment appear to correlate with CCA risk, with AMPLS in the MS region emerging as a strong predictor that could be used for preprocedural planning in order to minimize CCA risk.
- 7 February 2022
- Published by Wiley in Artificial Organs
- Vol. 46 (7) , 1305-1317
A computational framework for post‐TAVR cardiac conduction abnormality (CCA) risk assessment in patient‐specific anatomy
Background: Cardiac conduction abnormality (CCA)‐ one of the major persistent complications associated with transcatheter aortic valve replacement (TAVR) may lead to permanent pacemaker implantation. Localized stresses exerted by the device frame on the membranous septum (MS) which lies between the aortic annulus and the bundle of His, may disturb the cardiac conduction and cause the resultant CCA. We hypothesize that the area‐weighted average maximum principal logarithmic strain (AMPLS) in the MS region can predict the risk of CCA following TAVR.Methods: Rigorous finite element‐based analysis was conducted in two patients (Balloon expandable TAVR recipients) to assess post‐TAVR CCA risk. Following the procedure one of the patients required permanent pacemaker (PPM) implantation while the other did not (control case). Patient‐specific aortic root was modeled, MS was identified from the CT image, and the TAVR deployment was simulated. Mechanical factors in the MS region such as logarithmic strain, contact force, contact pressure, contact pressure index (CPI) and their time history during the TAVR deployment; and anatomical factors such as MS length, implantation depth, were analyzed.Results: Maximum AMPLS (0.47 and 0.37, respectively), contact force (0.92 N and 0.72 N, respectively), and CPI (3.99 and 2.86, respectively) in the MS region were significantly elevated in the PPM patient as compared to control patient.Conclusion: Elevated stresses generated by TAVR devices during deployment appear to correlate with CCA risk, with AMPLS in the MS region emerging as a strong predictor that could be used for preprocedural planning in order to minimize CCA risk.
- 7 December 2020
- Published by Wiley in Artificial Organs
- Vol. 45 (4) , E41-E52
Patient‐specific in vitro testing for evaluating TAVR clinical performance—A complementary approach to current ISO standard testing
Following in vitro tests established for surgical prosthetic heart valves, transcatheter aortic valves (TAV) are similarly tested in idealized geometries—excluding effects that may hamper TAVR performance in situ. Testing in vitro in pulse duplicator systems that incorporated patient‐specific replicas would enhance the testing veracity by bringing it closer to the clinical scenario. To that end we compare TAV hemodynamic performance tested in idealized geometries according to the ISO standard (baseline performance) to that obtained by testing the TAVs following deployment in patient‐specific replicas. Balloon‐expandable (n = 2) and self‐expandable (n = 3) TAVs were tested in an idealized geometry in mock‐circulation system (following ISO 5840‐3 guidelines) and compared to the measurements in a dedicated mock‐circulation system adapted for the five patient‐specific replicas. Patient‐specific deployments resulted in a decline in performance as compared to the baseline idealized testing, as well as a variation in performance that depended on the design features of each device that was further correlated with the radial expansion and eccentricity of the deployed TAV stent (obtained with CT‐scans of the deployed valves). By excluding the deployment effects in irregular geometries, the current idealized ISO testing is limited to characterize the baseline device performance. Utilizing patient‐specific anatomic contours provides performance indicators under more stringent conditions likely encountered in vivo. It has the potential to enhance testing and development complementary to the ISO standard, for improved TAV safety and effectiveness.
- 7 December 2020
- Published by Wiley in Artificial Organs
- Vol. 45 (4) , E41-E52
Patient‐specific in vitro testing for evaluating TAVR clinical performance—A complementary approach to current ISO standard testing
Following in vitro tests established for surgical prosthetic heart valves, transcatheter aortic valves (TAV) are similarly tested in idealized geometries—excluding effects that may hamper TAVR performance in situ. Testing in vitro in pulse duplicator systems that incorporated patient‐specific replicas would enhance the testing veracity by bringing it closer to the clinical scenario. To that end we compare TAV hemodynamic performance tested in idealized geometries according to the ISO standard (baseline performance) to that obtained by testing the TAVs following deployment in patient‐specific replicas. Balloon‐expandable (n = 2) and self‐expandable (n = 3) TAVs were tested in an idealized geometry in mock‐circulation system (following ISO 5840‐3 guidelines) and compared to the measurements in a dedicated mock‐circulation system adapted for the five patient‐specific replicas. Patient‐specific deployments resulted in a decline in performance as compared to the baseline idealized testing, as well as a variation in performance that depended on the design features of each device that was further correlated with the radial expansion and eccentricity of the deployed TAV stent (obtained with CT‐scans of the deployed valves). By excluding the deployment effects in irregular geometries, the current idealized ISO testing is limited to characterize the baseline device performance. Utilizing patient‐specific anatomic contours provides performance indicators under more stringent conditions likely encountered in vivo. It has the potential to enhance testing and development complementary to the ISO standard, for improved TAV safety and effectiveness.
- 27 August 2020
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 37 (18) , 2014-2022
Multi-Site Optical Monitoring of Spinal Cord Ischemia during Spine Distraction
Optimal surgical management of spine trauma will restore blood flow to the ischemic spinal cord. However, spine stabilization may also further exacerbate injury by inducing ischemia. Current electrophysiological technology is not capable of detecting acute changes in spinal cord blood flow or localizing ischemia. Further, alerts are delayed and unreliable. We developed an epidural optical device capable of directly measuring and immediately detecting changes in spinal cord blood flow using diffuse correlation spectroscopy (DCS). Herein we test the hypothesis that our device can continuously monitor blood flow during spine distraction. Additionally, we demonstrate the ability of our device to monitor multiple sites along the spinal cord and axially resolve changes in spinal cord blood flow. DCS-measured blood flow in the spinal cord was monitored at up to three spatial locations (cranial to, at, and caudal to the distraction site) during surgical distraction in a sheep model. Distraction was halted at 50% of baseline blood flow at the distraction site. We were able to monitor blood flow with DCS in multiple regions of the spinal cord simultaneously at ∼1 Hz. The distraction site had a greater decrement in flow than sites cranial to the injury (median −40 vs. −7%,). This pilot study demonstrated high temporal resolution and the capacity to axially resolve changes in spinal cord blood flow at and remote from the site of distraction. These early results suggest that this technology may assist in the surgical management of spine trauma and in corrective surgery of the spine.
- 27 August 2020
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 37 (18) , 2014-2022
Multi-Site Optical Monitoring of Spinal Cord Ischemia during Spine Distraction
Optimal surgical management of spine trauma will restore blood flow to the ischemic spinal cord. However, spine stabilization may also further exacerbate injury by inducing ischemia. Current electrophysiological technology is not capable of detecting acute changes in spinal cord blood flow or localizing ischemia. Further, alerts are delayed and unreliable. We developed an epidural optical device capable of directly measuring and immediately detecting changes in spinal cord blood flow using diffuse correlation spectroscopy (DCS). Herein we test the hypothesis that our device can continuously monitor blood flow during spine distraction. Additionally, we demonstrate the ability of our device to monitor multiple sites along the spinal cord and axially resolve changes in spinal cord blood flow. DCS-measured blood flow in the spinal cord was monitored at up to three spatial locations (cranial to, at, and caudal to the distraction site) during surgical distraction in a sheep model. Distraction was halted at 50% of baseline blood flow at the distraction site. We were able to monitor blood flow with DCS in multiple regions of the spinal cord simultaneously at ∼1 Hz. The distraction site had a greater decrement in flow than sites cranial to the injury (median −40 vs. −7%,). This pilot study demonstrated high temporal resolution and the capacity to axially resolve changes in spinal cord blood flow at and remote from the site of distraction. These early results suggest that this technology may assist in the surgical management of spine trauma and in corrective surgery of the spine.
- Open Access
- 4 August 2020
- Published by BMJ
- Vol. 12 (Suppl 1) , A22.2-A23
O-033 Computational fluid dynamics analysis to compare flow diversion efficacy of evolve and pipeline devices
Introduction Flow diversion has successfully treated aneurysm patients for more than a decade. Multiple devices with design variations in composition and braid structure have been released over this time with the primary goal of intraneurysmal flow reduction. Computational fluid dynamics (CFD) studies have been the most commonly used method to evaluate the effect of different pore structures on intraneurysmal flow. The goal of this study was to use CFD analysis to compare the flow diversion behavior of the second-generation release of the Surpass flow diverter (Surpass Evolve, Stryker Neurovascular) with the latest generation Pipeline device (Pipeline Flex Embolization Device with Shield, Medtronic Neurovascular). Methods Evolve and Pipeline flow diverters were deployed in silicone replicas of two patient-specific aneurysms (figure 1). The ‘treated’ replicas were scanned at a voxel resolution of 10.3 microns with a micro-CT scanner. Image slices encompassing the aneurysm neck were segmented. The centerline of each wire in the aneurysm neck region was manually traced and used to design the flow diverter covering the neck. The devices were manually registered and embedded in the aneurysm neck wall, i.e., the effect of wall apposition was not considered here. CFD was conducted in Fluent (ANSYS, Canonsburg, PA) by generating a volumetric mesh comprised of 2–4.5 Million polyhedral cells. An instantaneous, pulsatile, axisymmetric velocity profile was imposed at the cervical carotid entrance and pressures at the middle cerebral, anterior cerebral, and posterior communicating outlets were set to atmospheric. The kinetic energy of flow (velocity-squared) was averaged over the aneurysm volume at about 200 time-points over the cardiac cycle and used to compare the relative flow diversion efficacy of the two devices. Results The figure 1 shows the streamlines near systole color-coded by velocity for all 6 cases. A progressive qualitative reduction (from red to blue color) can be seen in the inflow ‘jet’ as well as intraneurysmal velocities from the Control (no device) to Pipeline to Evolve cases. The plots quantifying the kinetic energy with each device clearly show that the intraneurysmal flow activity with the Evolve device was less than with the Pipeline device. Conclusion The Evolve device produced greater reduction in intraneurysmal flow as compared to the Pipeline device in this computational study. In vivo studies are required to evaluate the endothelialization and biological efficacy of the devices. Disclosures C. Sadasivan: 1; C; Stryker Neurovascular, Vascular Simulations Inc. 2; C; Vascular Simulations Inc. 4; C; Vascular Simulations Inc. 6; C; Vascular Simulations Inc. B. Kovarovic: None. R. Ghosh: None. D. Fiorella: 1; C; Stryker Neurovascular, Medtronic Neurovascular. 2; C; Stryker Neurovascular, Medtronic Neurovascular. 4; C; Vascular Simulations Inc.
- 4 August 2020
- Published by BMJ
- Vol. 12 (Suppl 1) , A22.2-A23
Open AccessO-033 Computational fluid dynamics analysis to compare flow diversion efficacy of evolve and pipeline devices
Introduction Flow diversion has successfully treated aneurysm patients for more than a decade. Multiple devices with design variations in composition and braid structure have been released over this time with the primary goal of intraneurysmal flow reduction. Computational fluid dynamics (CFD) studies have been the most commonly used method to evaluate the effect of different pore structures on intraneurysmal flow. The goal of this study was to use CFD analysis to compare the flow diversion behavior of the second-generation release of the Surpass flow diverter (Surpass Evolve, Stryker Neurovascular) with the latest generation Pipeline device (Pipeline Flex Embolization Device with Shield, Medtronic Neurovascular). Methods Evolve and Pipeline flow diverters were deployed in silicone replicas of two patient-specific aneurysms (figure 1). The ‘treated’ replicas were scanned at a voxel resolution of 10.3 microns with a micro-CT scanner. Image slices encompassing the aneurysm neck were segmented. The centerline of each wire in the aneurysm neck region was manually traced and used to design the flow diverter covering the neck. The devices were manually registered and embedded in the aneurysm neck wall, i.e., the effect of wall apposition was not considered here. CFD was conducted in Fluent (ANSYS, Canonsburg, PA) by generating a volumetric mesh comprised of 2–4.5 Million polyhedral cells. An instantaneous, pulsatile, axisymmetric velocity profile was imposed at the cervical carotid entrance and pressures at the middle cerebral, anterior cerebral, and posterior communicating outlets were set to atmospheric. The kinetic energy of flow (velocity-squared) was averaged over the aneurysm volume at about 200 time-points over the cardiac cycle and used to compare the relative flow diversion efficacy of the two devices. Results The figure 1 shows the streamlines near systole color-coded by velocity for all 6 cases. A progressive qualitative reduction (from red to blue color) can be seen in the inflow ‘jet’ as well as intraneurysmal velocities from the Control (no device) to Pipeline to Evolve cases. The plots quantifying the kinetic energy with each device clearly show that the intraneurysmal flow activity with the Evolve device was less than with the Pipeline device. Conclusion The Evolve device produced greater reduction in intraneurysmal flow as compared to the Pipeline device in this computational study. In vivo studies are required to evaluate the endothelialization and biological efficacy of the devices. Disclosures C. Sadasivan: 1; C; Stryker Neurovascular, Vascular Simulations Inc. 2; C; Vascular Simulations Inc. 4; C; Vascular Simulations Inc. 6; C; Vascular Simulations Inc. B. Kovarovic: None. R. Ghosh: None. D. Fiorella: 1; C; Stryker Neurovascular, Medtronic Neurovascular. 2; C; Stryker Neurovascular, Medtronic Neurovascular. 4; C; Vascular Simulations Inc.